Tag: Malignant hyperthermia

Over 300 million surgeries are performed annually worldwide, and while anesthesia is remarkably safe for most, certain health conditions and patient-specific factors can make it profoundly risky. While very few people have absolute contraindications that prevent them from ever receiving anesthesia, many have significant relative risks that require careful management and optimized health before a procedure can proceed safely, addressing who cannot be given anesthesia without special precautions.

The true incidence of serotonin syndrome is unknown, as milder cases are often misdiagnosed or overlooked. This raises a critical question for clinicians: what can serotonin syndrome be confused with, and how can one differentiate it from its mimics?

Malignant hyperthermia (MH) occurs in approximately 1 in 100,000 adults receiving anesthetics, but the underlying genetic susceptibility may be far more common. This rare, but potentially fatal, pharmacogenetic disorder is triggered by a limited number of specific drugs. Knowing which drugs cause malignant hyperthermia is critical for patient safety during surgery.

Despite significant advancements in medical technology and safety protocols, making anesthesia safer than ever before, adverse events can still occur. For many patients, a key concern remains, **What happens if anesthesia goes wrong?** This question explores a range of potential issues, from minor side effects to rare but serious complications.

Idiosyncratic drug-induced liver injury (iDILI) has an estimated incidence of 19 in 100,000 people, making it a leading cause of acute liver failure in developed countries [1.2.4]. This highlights the serious nature of these rare events, but **what is an example of an idiosyncratic drug effect** and why do they occur?

For a healthy individual, the risk of death from anesthesia is remarkably low, estimated at less than 1 in a million during routine procedures. However, when considering what is the biggest risk of anesthesia, the answer is complex and dependent on the patient's specific health profile and the type of surgery.

Cardiovascular collapse with marked hyperkalemia has been reported in patients who received dantrolene alongside calcium channel blockers. This highlights a crucial warning regarding what should not be given with RYANODEX, a medication used for malignant hyperthermia. Ensuring patient safety depends on adhering to prescribing guidelines.

First introduced in 1967, dantrolene sodium, originally marketed under the brand name Dantrium, is a postsynaptic muscle relaxant used primarily to treat muscle spasticity. When asking, "What is another name for Dantrium?" the answer refers to its generic name, dantrolene, and other brands such as Revonto and Ryanodex.

Revonto is a brand name for the generic medication dantrolene sodium, a direct-acting skeletal muscle relaxant used to treat and prevent malignant hyperthermia (MH). While Revonto is a form of dantrolene, it differs from other brands and the generic equivalent in its specific formulation and reconstitution process.

Dantrolene carries a significant risk of liver damage (hepatotoxicity), with symptomatic hepatitis occurring in some patients. This guide details the populations and conditions for which this muscle relaxant is contraindicated, helping to clarify who should not use dantrolene for safety reasons.